Huge Announcement: Richter and Eli Lilly Enter Into a Partnership, the US Pharmaceutical Giant Also Acquires a Stake
6 Articles
6 Articles
Richter Gedeon has entered into an exclusive licensing agreement with Eli Lilly to develop new innovative gynaecological and cardiometabolic therapies. At the heart of the collaboration is Richter's proprietary Estetrol platform, which can be combined with Lilly's active ingredients. As part of the deal, Lilly will also buy $15 million worth of Richter shares, according to a statement published by Richter on Beth.
BUX was slightly down on Thursday morning, while Richter hit an all-time high at the opening after announcing a partnership with Eli Lilly. The mood on international markets was mixed, with the outlook for US technology stocks dampened by Nvidia's after-hours decline. In corporate news, the Richter deal was followed by Allianz's higher earnings guidance and KBC's strong quarter.
Eli Lilly acquired exclusive rights to manufacture and sell drugs combined with Richter's estrogen preparation.
Richter has signed an exclusive licensing agreement with the American Eli Lilly. The goal: to develop new, innovative gynecological medicines.
Richter has entered into an exclusive license agreement with Lilly to develop new innovative gynecological drugs.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
